Pharvaris (PHVS) Competitors $15.57 +0.09 (+0.58%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$16.02 +0.45 (+2.92%) As of 03/27/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHVS vs. ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, APLS, and BHVNShould you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Pharvaris vs. Alvotech Immunovant Viking Therapeutics Rhythm Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Merus Protagonist Therapeutics Apellis Pharmaceuticals Biohaven Pharvaris (NASDAQ:PHVS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk. Do analysts recommend PHVS or ALVO? Pharvaris currently has a consensus target price of $40.50, indicating a potential upside of 160.12%. Alvotech has a consensus target price of $18.00, indicating a potential upside of 73.75%. Given Pharvaris' higher probable upside, equities analysts plainly believe Pharvaris is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Alvotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer PHVS or ALVO? Pharvaris received 29 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 66.67% of users gave Pharvaris an outperform vote while only 50.00% of users gave Alvotech an outperform vote. CompanyUnderperformOutperformPharvarisOutperform Votes3666.67% Underperform Votes1833.33% AlvotechOutperform Votes750.00% Underperform Votes750.00% Is PHVS or ALVO more profitable? Pharvaris has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -38.52% -36.69% Alvotech -123.47%N/A -35.87% Does the media prefer PHVS or ALVO? In the previous week, Alvotech had 13 more articles in the media than Pharvaris. MarketBeat recorded 15 mentions for Alvotech and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.87 beat Alvotech's score of 0.58 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alvotech 2 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, PHVS or ALVO? Pharvaris has higher earnings, but lower revenue than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$109.18M-$2.80-5.56Alvotech$391.87M7.97-$551.73M-$1.85-5.60 Which has more risk and volatility, PHVS or ALVO? Pharvaris has a beta of -3.02, suggesting that its share price is 402% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. SummaryPharvaris beats Alvotech on 8 of the 14 factors compared between the two stocks. Remove Ads Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHVS vs. The Competition Export to ExcelMetricPharvarisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$814.16M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-5.567.2023.1319.03Price / SalesN/A226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book1.966.476.944.33Net Income-$109.18M$141.90M$3.20B$247.06M7 Day Performance1.10%-3.20%-2.33%-0.37%1 Month Performance-2.08%-5.64%2.84%-3.85%1 Year Performance-32.63%-7.47%10.74%1.27% Pharvaris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHVSPharvaris1.4367 of 5 stars$15.57+0.6%$40.50+160.1%-33.7%$814.16MN/A-5.5630Gap UpALVOAlvotech2.0025 of 5 stars$11.31+0.1%$18.00+59.2%-18.3%$3.41B$391.87M-6.111,026Earnings ReportNews CoverageIMVTImmunovant2.4856 of 5 stars$20.02+2.6%$42.90+114.3%-42.2%$3.40BN/A-7.64120VKTXViking Therapeutics4.3386 of 5 stars$29.83-3.4%$97.67+227.4%-68.6%$3.35BN/A-29.8320Analyst ForecastRYTMRhythm Pharmaceuticals4.4437 of 5 stars$52.34+2.7%$69.31+32.4%+28.0%$3.31B$130.13M-12.09140Analyst RevisionSRRKScholar Rock3.504 of 5 stars$34.72+0.3%$40.86+17.7%+115.9%$3.29B$33.19M-14.77140Analyst ForecastInsider TradeCRNXCrinetics Pharmaceuticals4.314 of 5 stars$35.20+2.1%$72.64+106.4%-21.4%$3.28B$1.04M-9.44210Analyst ForecastPositive NewsMRUSMerus2.2027 of 5 stars$47.22+0.3%$85.31+80.7%+0.2%$3.26B$36.13M-11.9537PTGXProtagonist Therapeutics3.601 of 5 stars$53.01-3.2%$61.22+15.5%+73.6%$3.25B$434.43M19.93120Positive NewsAPLSApellis Pharmaceuticals4.354 of 5 stars$25.11+1.8%$45.53+81.3%-58.5%$3.15B$781.37M-12.37770Positive NewsBHVNBiohaven3.9184 of 5 stars$29.73+2.0%$63.15+112.4%-50.3%$3.03BN/A-3.18239 Remove Ads Related Companies and Tools Related Companies Alvotech Alternatives Immunovant Alternatives Viking Therapeutics Alternatives Rhythm Pharmaceuticals Alternatives Scholar Rock Alternatives Crinetics Pharmaceuticals Alternatives Merus Alternatives Protagonist Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHVS) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
